What are the recommended diagnostic tests, treatment indications, first‑line antiviral therapies, and vaccination strategy for hepatitis B infection?

Hepatitis B: Diagnostic Tests, Treatment Indications, First-Line Therapies, and Vaccination Strategy

Diagnostic Tests

All patients with suspected or confirmed hepatitis B require a comprehensive serologic panel including HBsAg, anti-HBs, total anti-HBc (IgG + IgM), anti-HBc IgM, HBeAg/anti-HBe, and quantitative HBV DNA, along with liver biochemistry (ALT, AST, bilirubin, albumin, alkaline phosphatase, PT/INR) and complete blood count with platelets. 1

Core Serologic Markers

• HBsAg persistence for >6 months confirms chronic hepatitis B infection 1
• High-titer anti-HBc IgM indicates acute infection; low or absent titers suggest chronic infection 1
• HBeAg positivity with anti-HBe negativity signals active viral replication and guides treatment decisions 1
• Quantitative HBV DNA measurement using real-time PCR assays is essential for diagnosis, treatment decisions, and monitoring 2, 1
• Results should be expressed in IU/mL using WHO international standards for comparability 2

Baseline Imaging and Additional Testing

• Baseline abdominal ultrasound is mandatory for all HBsAg-positive individuals ≥20 years to screen for hepatocellular carcinoma 1
• Test for anti-HCV in all hepatitis B patients 2, 1
• Test for anti-HDV in persons from endemic regions (Mediterranean, Middle East, parts of Africa) or with injection-drug use history 2, 1
• Test for anti-HIV in high-risk groups (men who have sex with men, injection-drug users, multiple sexual partners) 2, 1
• Assess IgG anti-HAV and vaccinate non-immune individuals 2, 1

Fibrosis Assessment

• Liver biopsy is recommended in patients with intermittent or persistent ALT elevation to grade inflammation and stage fibrosis 1
• Transient elastography (FibroScan) values >7.8 kPa suggest advanced fibrosis 1
• Biopsy is not required in patients with clinical evidence of cirrhosis or when treatment is indicated regardless of fibrosis stage 2

Treatment Indications

Treatment should be initiated when HBV DNA ≥20,000 IU/mL in HBeAg-positive patients or ≥2,000 IU/mL in HBeAg-negative patients with elevated ALT and evidence of liver inflammation or fibrosis. 1, 3

Specific Treatment Criteria

• HBeAg-positive chronic hepatitis B: Treat when HBV DNA ≥20,000 IU/mL with elevated ALT 1
• HBeAg-negative chronic hepatitis B: Treat when HBV DNA ≥2,000 IU/mL with elevated ALT 1
• Cirrhotic patients require treatment regardless of ALT or HBV DNA levels to prevent decompensation 2
• Patients with evidence of moderate-to-severe inflammation or significant fibrosis on biopsy should be treated 2, 1

First-Line Antiviral Therapies

Pegylated interferon alfa-2a, entecavir, and tenofovir are the recommended first-line treatment options for chronic hepatitis B. 4

Nucleos(t)ide Analogues

• Entecavir and tenofovir are preferred oral agents due to high potency and high genetic barrier to resistance 3, 4
• These agents suppress HBV DNA replication and improve liver inflammation and fibrosis 4
• Lamivudine is no longer recommended as first-line therapy due to high resistance rates 3

Pegylated Interferon

• Pegylated interferon alfa-2a is an option for selected patients, particularly those with HBV genotype A or B 2, 4
• Finite treatment duration (typically 48 weeks) is an advantage over indefinite nucleos(t)ide therapy 3
• Not suitable for patients with decompensated cirrhosis 2

Treatment Goal

• The goal is immunologic cure, defined as loss of HBsAg with sustained HBV DNA suppression 4
• This reduces risk of cirrhosis progression and hepatocellular carcinoma, particularly in non-cirrhotic patients 2

Vaccination Strategy

Universal infant vaccination beginning within 24 hours of birth is the cornerstone of the comprehensive strategy to eliminate hepatitis B transmission. 2

Perinatal Prevention

• All pregnant women must be screened for HBsAg at the first prenatal visit 2
• Infants born to HBsAg-positive mothers require both hepatitis B vaccine and HBIG within 12 hours of birth 2
• This combination is 95% effective in preventing perinatal transmission 2
• HBV DNA testing for HBsAg-positive pregnant women is recommended, with maternal antiviral therapy when HBV DNA >200,000 IU/mL to reduce perinatal transmission 2

Universal Infant Vaccination

• All medically stable infants weighing ≥2,000 grams should receive the first hepatitis B vaccine dose within 24 hours of birth 2, 4
• This serves as a safety net for infants born to HBV-infected mothers not identified prenatally 2
• The complete series includes three doses, with the final dose administered no earlier than 24 weeks (164 days) of age 5

Catch-Up Vaccination

• All previously unvaccinated children aged <19 years should receive routine hepatitis B vaccination 2
• Vaccination record reviews should be implemented for all children aged 11-12 years 2

Adult Vaccination

• Vaccination is recommended for adults at risk for HBV infection, including those requesting protection without acknowledgment of a specific risk factor 2
• High-risk settings requiring universal vaccination include STD/HIV testing facilities, drug-abuse treatment centers, correctional facilities, and healthcare settings serving injection-drug users or men who have sex with men 2
• Sexual and household contacts of HBsAg-positive persons should be tested and vaccinated if seronegative 2

Post-Vaccination Testing

• Infants of HBsAg-positive mothers should be tested at 9-15 months of age 2
• Healthcare workers and other high-risk individuals should be tested 1-2 months after the last vaccine dose 2
• Chronic hemodialysis patients require annual follow-up testing 2

Prevention Counseling for Infected Persons

HBsAg-positive persons must have sexual contacts vaccinated and use barrier protection during intercourse if partners are not vaccinated or naturally immune. 2

Transmission Prevention Measures

• Do not share toothbrushes or razors 2
• Cover open cuts and scratches 2
• Clean blood spills with detergent or bleach 2
• Do not donate blood, organs, or sperm 2
• Abstinence or only limited alcohol use is recommended to reduce liver injury 2, 1

Important Clarifications

• Children and adults who are HBsAg-positive can participate in all activities including contact sports and should not be excluded from daycare or school 2
• They can share food, utensils, and kiss others 2
• Breastfeeding is not contraindicated in HBV-infected mothers 2

Monitoring and Surveillance

ALT should be monitored every 3-6 months in all HBsAg-positive patients to detect active inflammation. 1, 3

Hepatocellular Carcinoma Surveillance

• HCC surveillance with ultrasound every 6 months is mandatory for high-risk patients, particularly those ≥40 years of age 2, 1, 3
• Alpha-fetoprotein may be obtained but has limited specificity 1

Common Pitfalls

• Isolated anti-HBc positivity requires HBV DNA testing to distinguish occult HBV, resolved infection, or false-positive results 1
• During the "window period," isolated anti-HBc IgM may appear after HBsAg loss but before anti-HBs development; repeat testing in 3-6 months is advised 1
• Occult HBV (HBsAg-negative, HBV DNA-positive) occurs especially in HIV-coinfected patients; test HBV DNA when anti-HBc is positive with unexplained transaminitis 1